Lanxess invested $10m at $28.49 per share as part of BioAmber's $30m series C round.

US-based Enanta Pharmaceuticals Inc has raised $56m in its IPO. The company priced four million shares at $14 per share for an initial market cap of approximately $236 million.

Marin has set its price range at between $11 and $13 for each of the seven million shares it plans to sell, with a further 1.05 million available if the flotation goes well.

Enanta would have an initial market capitalisation of $252m at $15 per share, according to its regulatory filing.

US-based Silver Spring, backed by Google Ventures, Kleiner Perkins Caufield & Byers and Northgate Capital, has set its IPO range at $16-$18 for 3.7 million shares.

Ambit, formerly known as Aventa Biosciences, has hired investment banks Citigroup and Leerink Swann for its $57.5m initial public offering (IPO) after raising more than $165m.

Globes said other Israeli life sciences companies were also planning their US initial public offering, including Kamada, Alcobra and Home Skinovations.

Nokia-backed online advertising services company Rocket Fuel has reportedly selected Credit Suisse and Citigroup to lead its planned initial public offering later this year.